GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (STU:GE9) » Definitions » PS Ratio

Genmab AS (STU:GE9) PS Ratio : 5.00 (As of Dec. 13, 2024)


View and export this data going back to . Start your Free Trial

What is Genmab AS PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Genmab AS's share price is €204.40. Genmab AS's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €40.91. Hence, Genmab AS's PS Ratio for today is 5.00.

Good Sign:

Genmab AS stock PS Ratio (=4.88) is close to 10-year low of 4.75

The historical rank and industry rank for Genmab AS's PS Ratio or its related term are showing as below:

STU:GE9' s PS Ratio Range Over the Past 10 Years
Min: 4.75   Med: 23.01   Max: 72.69
Current: 4.88

During the past 13 years, Genmab AS's highest PS Ratio was 72.69. The lowest was 4.75. And the median was 23.01.

STU:GE9's PS Ratio is ranked better than
66.9% of 1015 companies
in the Biotechnology industry
Industry Median: 8.73 vs STU:GE9: 4.88

Genmab AS's Revenue per Sharefor the three months ended in Sep. 2024 was €11.63. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €40.91.

Good Sign:

Genmab AS has shown predictable revenue and earnings growth.

During the past 12 months, the average Revenue per Share Growth Rate of Genmab AS was 19.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 17.70% per year. During the past 5 years, the average Revenue per Share Growth Rate was 36.40% per year. During the past 10 years, the average Revenue per Share Growth Rate was 38.10% per year.

During the past 13 years, Genmab AS's highest 3-Year average Revenue per Share Growth Rate was 326.80% per year. The lowest was -20.40% per year. And the median was 34.45% per year.

Back to Basics: PS Ratio


Genmab AS PS Ratio Historical Data

The historical data trend for Genmab AS's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS PS Ratio Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.57 16.05 20.64 13.38 8.62

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.81 8.62 7.72 6.02 5.31

Competitive Comparison of Genmab AS's PS Ratio

For the Biotechnology subindustry, Genmab AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's PS Ratio falls into.



Genmab AS PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Genmab AS's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=204.40/40.908
=5.00

Genmab AS's Share Price of today is €204.40.
Genmab AS's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €40.91.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Genmab AS  (STU:GE9) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Genmab AS PS Ratio Related Terms

Thank you for viewing the detailed overview of Genmab AS's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines